These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 8837861)

  • 21. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
    Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
    Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization in vitro and in vivo of progressively adriamycin-resistant B16-BL6 mouse melanoma cells.
    Ganapathi R; Grabowski D; Schmidt H; Bell D; Melia M
    Cancer Res; 1987 Jul; 47(13):3464-8. PubMed ID: 2884031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance.
    Chen G; Waxman DJ
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1271-7. PubMed ID: 7562498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence for nutrient modulation of tumor phenotype: impact of tyrosine and phenylalanine restriction.
    Elstad CA; Meadows GG; Aslakson CJ; Starkey JR
    Adv Exp Med Biol; 1994; 354():171-83. PubMed ID: 7520663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Murine splenocyte migration inhibition assay I. Detection of differential responses to murine leukemia P388 and its adriamycin-resistant subline P388/ADR.
    Nori M; Gothoskar BP
    Neoplasma; 1983; 30(3):287-93. PubMed ID: 6223231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circumvention of adriamycin resistance: effect of 2-methyl-1,4-naphthoquinone (vitamin K3) on drug cytotoxicity in sensitive and MDR P388 leukemia cells.
    Parekh HK; Mansuri-Torshizi H; Srivastava TS; Chitnis MP
    Cancer Lett; 1992 Jan; 61(2):147-56. PubMed ID: 1730138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of microenvironmental pH on adriamycin resistance.
    Alabaster O; Woods T; Ortiz-Sanchez V; Jahangeer S
    Cancer Res; 1989 Oct; 49(20):5638-43. PubMed ID: 2790781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circumvention of drug resistance of P388/R cells by the combination of adriamycin and mitoxantrone with hyperthermia (42 degrees C).
    Juvekar AS; Chitnis MP
    Neoplasma; 1991; 38(2):207-11. PubMed ID: 2041579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo reversibility of multidrug resistance by the MDR-modulator dexniguldipine (niguldipine derivative B859-35) and by verapamil.
    Dietel M; Boss H; Reymann A; Pest S; Seidel A
    J Exp Ther Oncol; 1996 Jan; 1(1):23-9. PubMed ID: 9414385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance to anthrapyrazoles and anthracyclines in multidrug-resistant P388 murine leukemia cells: reversal by calcium blockers and calmodulin antagonists.
    Klohs WD; Steinkampf RW; Havlick MJ; Jackson RC
    Cancer Res; 1986 Sep; 46(9):4352-6. PubMed ID: 3460695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of subcellular distribution of doxorubicin in multidrug-resistant P388/ADR mouse leukemia cells by the chemosensitizer ((2-isopropyl-1-(4-[3-N-methyl-N-(3,4-dimethoxy-beta- phenethyl)amino]propyloxy)-benzenesulfonyl))indolizine.
    Jaffrézou JP; Levade T; Chatelain P; Laurent G
    Cancer Res; 1992 Dec; 52(23):6440-6. PubMed ID: 1423291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of buthionine sulfoximine and ethacrynic acid on cytotoxic activity of mitomycin C analogues BMY 25282 and BMY 25067.
    Xu BH; Singh SV
    Cancer Res; 1992 Dec; 52(23):6666-70. PubMed ID: 1423311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reversal of drug sensitivity in MDR subline of P388 leukemia by gene-targeted antisense oligonucleotide.
    Nakashima E; Matsushita R; Negishi H; Nomura M; Harada S; Yamamoto H; Miyamoto K; Ichimura F
    J Pharm Sci; 1995 Oct; 84(10):1205-9. PubMed ID: 8801335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Specificity of the suppression of metastatic phenotype by tyrosine and phenylalanine restriction.
    Elstad CA; Meadows GG; Abdallah RM
    Clin Exp Metastasis; 1990; 8(5):393-416. PubMed ID: 2202533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
    Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
    J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploring multidrug resistance using rhodamine 123.
    Kessel D
    Cancer Commun; 1989; 1(3):145-9. PubMed ID: 2639727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tyrosine and phenylalanine restriction induces G0/G1 cell cycle arrest in murine melanoma in vitro and in vivo.
    Fu YM; Yu ZX; Ferrans VJ; Meadows GG
    Nutr Cancer; 1997; 29(2):104-13. PubMed ID: 9427972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
    Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y
    Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of a new triazinoaminopiperidine derivative on adriamycin accumulation and retention in cells displaying P-glycoprotein-mediated multidrug resistance.
    Léonce S; Pierré A; Anstett M; Pérez V; Genton A; Bizzari JP; Atassi G
    Biochem Pharmacol; 1992 Nov; 44(9):1707-15. PubMed ID: 1360210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of two distinct intracellular sites that contribute to the modulation of multidrug resistance in P388/ADR cells expressing P-glycoprotein.
    Mayer LD; Lim KT; Hartley D
    J Exp Ther Oncol; 2002; 2(2):107-20. PubMed ID: 12415627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.